Ohr Pharmaceutical to Present at Upcoming Investment Conferences admin, 8 May 2025 Download PDF NEW YORK, March 02, 2016 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the upcoming 36th Annual Cowen & Company Global Healthcare Conference, and the…
Ohr Pharmaceutical Presents New Interim Phase 2 Clinical Data Showing Its OHR/AVR118 Drug to Be Safe, Effective Treatment of Severe Wasting Disorder (Cachexia) in Late Stage Cancer Patients admin, 8 May 2025 Download PDF Selectively Inhibits Inflammatory Immune Response DOVER, DE — (MARKET WIRE) — 12/08/09 — Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that interim data from the Company’s Phase 2 clinical trial of OHR/AVR118 demonstrate that the drug safely and effectively restores strength and vitality to patients suffering with Cachexia,…
Ohr Pharmaceutical Presents Biodistribution and Safety Data on Squalamine Eye Drops at ARVO 2012 Annual Meeting admin, 30 April 20251 May 2025 Download PDF Key Study Demonstrates Therapeutic Potential for Treating Wet-AMD NEW YORK, NY — (Marketwire) — 05/07/12 — Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that it presented a poster presentation titled “A Novel Eye Drop Formulation of Squalamine For Exudative AMD: Evaluation Of Ocular Distribution And Ocular Safety In…
Ohr Pharmaceutical to Present at the 16th Annual BIO CEO & Investor Conference admin, 30 April 20251 May 2025 Download PDF NEW YORK, NY — (Marketwired) — 02/04/14 — Ohr Pharmaceutical (NASDAQ: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that Irach Taraporewala, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 16th Annual…